| __timestamp | Ligand Pharmaceuticals Incorporated | Novartis AG |
|---|---|---|
| Wednesday, January 1, 2014 | 9136000 | 17345000000 |
| Thursday, January 1, 2015 | 5807000 | 17404000000 |
| Friday, January 1, 2016 | 5571000 | 17520000000 |
| Sunday, January 1, 2017 | 5366000 | 17175000000 |
| Monday, January 1, 2018 | 6337000 | 18407000000 |
| Tuesday, January 1, 2019 | 11347000 | 14425000000 |
| Wednesday, January 1, 2020 | 30419000 | 15121000000 |
| Friday, January 1, 2021 | 62176000 | 15867000000 |
| Saturday, January 1, 2022 | 52827000 | 15486000000 |
| Sunday, January 1, 2023 | 35049000 | 12472000000 |
| Monday, January 1, 2024 | 12827000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. From 2014 to 2023, Novartis AG and Ligand Pharmaceuticals Incorporated have shown contrasting trends in their cost of revenue. Novartis, a global healthcare giant, consistently maintained a high cost of revenue, peaking in 2018 with a 10% increase from 2017. However, by 2023, it saw a significant 32% decline, reflecting strategic cost management or market shifts. In contrast, Ligand Pharmaceuticals, a smaller player, experienced a dramatic rise, with costs surging by over 500% from 2014 to 2021, before stabilizing. This divergence highlights the varied strategies and market pressures faced by large and small pharmaceutical companies. As the industry continues to innovate, these trends offer insights into how companies manage their financial health amidst global challenges.
Cost of Revenue Trends: Johnson & Johnson vs Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Novartis AG vs Vertex Pharmaceuticals Incorporated
Cost of Revenue Comparison: Novartis AG vs Ionis Pharmaceuticals, Inc.
Cost of Revenue Trends: Novartis AG vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Ligand Pharmaceuticals Incorporated
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs Ligand Pharmaceuticals Incorporated
Grifols, S.A. vs Ligand Pharmaceuticals Incorporated: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: ADMA Biologics, Inc. vs Ligand Pharmaceuticals Incorporated
Cost of Revenue Trends: Bausch Health Companies Inc. vs Ligand Pharmaceuticals Incorporated
Analyzing Cost of Revenue: Ligand Pharmaceuticals Incorporated and Dyne Therapeutics, Inc.
Cost Insights: Breaking Down Ligand Pharmaceuticals Incorporated and Evotec SE's Expenses